Actively Recruiting

Phase 2
Age: 10Years +
All Genders
NCT06551844

Adaptive Dengue Antiviral Platform Trial

Led by Oxford University Clinical Research Unit, Vietnam · Updated on 2026-04-30

500

Participants Needed

2

Research Sites

245 weeks

Total Duration

On this page

Sponsors

O

Oxford University Clinical Research Unit, Vietnam

Lead Sponsor

H

Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection * Primary objectives: * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection * To assess the safety and tolerability of the experimental drug(s) in dengue patients * Secondary objective: * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters

CONDITIONS

Official Title

Adaptive Dengue Antiviral Platform Trial

Who Can Participate

Age: 10Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Female or male patients with clinical diagnosis of dengue virus infection and less than 48 hours of fever
  • Positive NS1 rapid diagnostic test
  • Age 10 years or older (depending on therapeutic license, may require 18+ years)
  • Able to provide written informed consent or assent
  • Agree to stay in hospital for intervention duration (usually 5 days) and attend follow-up visits at 30 and 60 days post enrollment
Not Eligible

You will not qualify if you...

  • Severe dengue at baseline including shock, respiratory distress, severe bleeding, or organ involvement (AST/ALT >1000 U/L, impaired consciousness, multiple organ dysfunction)
  • Pregnancy or breastfeeding
  • Signs of alternative diagnoses such as pneumonia or sepsis
  • Renal failure with baseline eGFR <30 ml/min
  • History or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders
  • Allergic disease or known hypersensitivity to study product components (mild non-medication allergies allowed)
  • Any condition that may complicate study participation or participant well-being
  • Participation in another investigational drug study within the past month

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Universiti Malaya Medical Centre

Kuala Lumpur, Malaysia, 59100

Not Yet Recruiting

2

Hospital for Tropical Diseases, Ho Chi Minh city

Ho Chi Minh City, Vietnam, 700000

Actively Recruiting

Loading map...

Research Team

S

Sophie Yacoub, MD., PhD.

CONTACT

C

Clinical Trials Unit Oxford University Clinical Research Unit

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Adaptive Dengue Antiviral Platform Trial | DecenTrialz